Evotec SEEvotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Tag Archive for: CRO
Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).
Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.
London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.
British drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North Americas largest discovery CROs
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
UK-based CRO Cresset has expanded its senior leadership team with the appointment of Nick Foster as Vice President of their Discovery CRO business.
The new Krakow headquarters of preclinical CRO Selvita have opened.